HiLabs Announces Closing of $39 Million Series B Financing to Advance its AI-powered Data Management Solutions for Healthcare Organizations [Yahoo! Finance]
LowReport
HiLabs Announces Closing of $39 Million Series B Financing to Advance its AI-powered Data Management Solutions for Healthcare Organizations [Yahoo! Finance]
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $73.00 to $50.00. They now have a "buy" rating on the stock.
LowReport
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $73.00 to $50.00. They now have a "buy" rating on the stock.
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at HC Wainwright from $105.00 to $95.00. They now have a "buy" rating on the stock.
LowReport
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at HC Wainwright from $105.00 to $95.00. They now have a "buy" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: